Prostate Cancer Clinical Trials in Washington

Showing 161-180 of 184 trials

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

NCT00385580

The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.

Prostate Cancer

Bristol-Myers Squibb94 participantsStarted Jan 2007

Los Angeles, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPhase 242 miles

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469

The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors) who are suitable candidates for prostatectomy (surgery to remove all or part of the prostate gland).

Prostate Cancer

Janssen Research & Development, LLC58 participantsStarted Nov 2009

Boston, Massachusetts, United States • Houston, Texas, United States • Seattle, Washington, United States +1 more locations

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Prostate Cancer Trials in Other Cities

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Study of Individualized Amonafide to Treat Prostate Cancer

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Markers for Early Detection of Prostate Cancer

Shorter Radiation Schedule for the Treatment of Prostate Cancer

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Sutent Maintenance After Response to Taxotere

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Other Conditions in Washington